title: Management of acute ischemic stroke.
abstract: Stroke is one of the most common causes of morbidity and mortality in hospitalized patients in the United States. A proper understanding of stroke mechanisms helps to guide specific case management. The only therapy approved by the US Food and Drug Administration for the management of acute ischemic stroke is initiation of intravenous recombinant tissue plasminogen activator within 3 hours of symptom onset. Other treatment options include intra-arterial recombinant tissue plasminogen activator, mechanical thrombectomy, clot retrieval, or a combination of these approaches. In this article, we provide an evidence-based review of the diagnostic approach for acute ischemic stroke, including recognizing common stroke mimics. We detail the initial medical management of acute stroke and the medical and surgical therapeutic interventions for patients who have sustained acute ischemic stroke.
authors.affiliation: Neurology Department, Loyola University Health System, Maywood, IL 60153, USA. smoralesvidal@lumc.edu
authors.forename: Sarkis Morales
authors.initials: SM
authors.lastname: Vidal
authors.forename: Farrukh S
authors.initials: FS
authors.lastname: Chaudhry
authors.forename: Michael
authors.initials: M
authors.lastname: Schneck
mesh_terms: D001927:Brain Diseases / Q000175:diagnosis; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D057510:Endovascular Procedures / Q000379:methods*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D059906:Neuroimaging / Q000379:methods; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator